Table 4. Association between rs6795970 genotypes and AF recurrence in three different genetic models.
| Group | Genotype | No recurrence, n% | AF recurrence, n% | Recurrence rate (%) | Pa | Additive model (adjusted) (AA vs.GA vs. GG) |
Dominant model (adjusted) (AA + GA vs. GG) |
Recessive model (adjusted) (AA vs. GG + GA) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | Pb | OR(95%CI) | Pb | OR (95%CI) | Pb | ||||||
| All AF patients | GG | 226 (59.6) | 99 (81.8) | 30.5 | 1.42 × 10-5 | 0.36 (0.22~0.60) | 7.04 × 10-5 | 0.29 (0.16~0.50) | 9.31 × 10−6 | 0.82 (0.21~3.24) | 0.780 |
| GA | 141 (37.2) | 19 (15.7) | 11.9 | ||||||||
| AA | 12 (3.2) | 3 (2.5) | 20.0 | ||||||||
| History of AF ≥36 months group | GG | 62 (58.5) | 58 (82.9) | 48.3 | 0.002 | 0.33 (0.17~0.66) | 0.002 | 0.30 (0.14~0.63) | 0.002 | 0.29 (0.03~2.68) | 0.274 |
| GA | 38 (35.8) | 11 (15.7) | 22.4 | ||||||||
| AA | 6 (5.7) | 1 (1.4) | 14.3 | ||||||||
| History of AF <36 months group | GG | 164 (60.1) | 41 (80.4) | 20.0 | 0.004 | 0.43 (0.21~0.86) | 0.018 | 0.32 (0.15~0.69) | 0.004 | 2.02 (0.37~11.07) | 0.419 |
| GA | 103 (37.7) | 8 (15.7) | 7.2 | ||||||||
| AA | 6 (2.2) | 2 (3.9) | 25.0 | ||||||||
| Paroxysmal AF group | GG | 154 (58.6) | 53 (79.1) | 25.6 | 0.005 | 0.41 (0.21~0.78) | 0.007 | 0.32 (0.16~0.66) | 0.002 | 0.97 (0.18~5.32) | 0.974 |
| GA | 100 (38.0) | 12 (17.9) | 10.7 | ||||||||
| AA | 9 (3.4) | 2 (3.0) | 18.2 | ||||||||
| Non-paroxysmal AF group | GG | 72 (62.1) | 46 (85.2) | 39.0 | 0.004 | 0.34 (0.16~0.75) | 0.007 | 0.28 (0.12~0.66) | 0.004 | 0.80 (0.07~9.62) | 0.860 |
| GA | 41 (35.3) | 7 (13.0) | 14.6 | ||||||||
| AA | 3 (2.6) | 1 (1.9) | 25.0 | ||||||||
Note: AF: atrial fibrillation. a: P values were calculated from a case-control analysis using the Chi-square test. b: P values were calculated by a multivariable logistic regression analysis after adjustment for clinical variables including sex, age (≥60 vs. <60 years old), AF subtype, history of AF (≥36 vs. <36 months), LAD (≥40 vs. <40 mm), LVEF, hypertension, coronary heart disease, rheumatic heart disease, cerebral embolism, diabetes, smoking, alcohol, linear ablations, CFAEs ablations, cardioversion during ablation and previous use of amiodarone, BB, CCB and ACEI/ARB.